Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Change In Receivables : $0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Change In Receivables?

Chugai Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was $0 Mil. It means Chugai Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Chugai Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was $0 Mil. It means Chugai Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Chugai Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was $1,600 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Chugai Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 92.30.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Chugai Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was $5,520 Mil.

Chugai Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Chugai Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Change In Receivables Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Chugai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Chugai Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Chugai Pharmaceutical Co (OTCPK:CHGCF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Chugai Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1599.728	/	1581.573	*	91
=	92.30

2. In Ben Graham's calculation of liquidation value, Chugai Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Chugai Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5103.278	-	1706.844	+	0.75 * 1599.728	+	0.5 * 1846.78
=	5,520

Chugai Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CHGCY:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines

From GuruFocus

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

T. Rowe Price Japan Fund Makes 4 New Buys in 3rd Quarter

By David Goodloe David Goodloe • 10-19-2016

T. Rowe Price Japan Fund Comments on Chugai Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 06-19-2020

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

By PRNewswire PRNewswire • 03-02-2023

Jean Hynes Adds to Chugai Pharmaceutical Stake

By Kyle Ferguson Kyle Ferguson • 08-22-2016